The present disclosure relates to a composition to aid in heavy metal detox. Metallothioneins (MT) are a family of cysteine-rich enzymes in the body that help remove and regulate heavy metals, copper, and other metals. Amino Acids in combination with zinc and/or molybdenum may provide improved production of MT over amino acid or zinc supplements alone. Additionally, Vitamin B6, Molybdenum, and Boron may be included to further enhance the efficacy of the composition.

The present invention relates to pharmaceutical, dietary and/or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H.sub.2S) so to feed the redox buffer capacity and to boost the natural ability to compensate both oxidative and reductive stress.

The invention further relates to the use of the aforementioned compositions to correct signs of metabolic derangements such as: oxy-redox imbalances including reductive stress, mitochondrial dysfunction and bioenergetics, insulin resistance, endothelial dysfunction and hyperhomocysteinemia. Accordingly, the composition of the present invention can be used as a medicament for the treatment of hypertension, atherosclerosis and cardiovascular disease, erectile dysfunction, viral infections and inflammatory lung injuries, diabetes and PCOS, autoimmune diseases, neurodegeneration, repeated implantation failure and repeated miscarriage and infertility in both men and women.

The present invention relates to pharmaceutical, dietary and/or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H.sub.2S) so to feed the redox buffer capacity and to boost the natural ability to compensate both oxidative and reductive stress.

The invention further relates to the use of the aforementioned compositions to correct signs of metabolic derangements such as: oxy-redox imbalances including reductive stress, mitochondrial dysfunction and bioenergetics, insulin resistance, endothelial dysfunction and hyperhomocysteinemia. Accordingly, the composition of the present invention can be used as a medicament for the treatment of hypertension, atherosclerosis and cardiovascular disease, erectile dysfunction, viral infections and inflammatory lung injuries, diabetes and PCOS, autoimmune diseases, neurodegeneration, repeated implantation failure and repeated miscarriage and infertility in both men and women.

The present invention relates to pharmaceutical, dietary and/or food compositions exerting the ability to activate the endogenous production of hydrogen sulfide (H.sub.2S) so to feed the redox buffer capacity and to boost the natural ability to compensate both oxidative and reductive stress.

The invention further relates to the use of the aforementioned compositions to correct signs of metabolic derangements such as: oxy-redox imbalances including reductive stress, mitochondrial dysfunction and bioenergetics, insulin resistance, endothelial dysfunction and hyperhomocysteinemia. Accordingly, the composition of the present invention can be used as a medicament for the treatment of hypertension, atherosclerosis and cardiovascular disease, erectile dysfunction, viral infections and inflammatory lung injuries, diabetes and PCOS, autoimmune diseases, neurodegeneration, repeated implantation failure and repeated miscarriage and infertility in both men and women.

A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.

A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.

A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.

The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.

The present invention relates to an ophthalmic composition for suppressing eye dryness, comprising at least one selected from the group consisting of chondroitin sulfate having a weight average molecular weight of 30,000 to 50,000 and a salt thereof.

The present disclosure provides a food for hangover and liver protection and a producing method thereof. The method includes: providing the raw materials of particular percentages by weight, wherein the prepared turmeric powder accounts for 25%-35% of the provided raw materials; the prepared kudzu isoflavone powder accounts for 30%-40% of the provided raw materials; the prepared Primula sieboldii root powder accounts for 20%-30% of the provided raw materials; the prepared fruit extract accounts for 5%-14% of the provided raw materials; and the prepared vitamin complex accounts for 1%-2% of the provided raw materials; performing a sieving pretreatment on each of the provided raw materials; putting the pretreated raw materials into a wet granulator to perform a mix process for obtaining the food; and performing a testing process on the mixed food, and re-performing the mix process on the tested food in response to the tested food being unqualified.